Piper Sandler Maintains Overweight on RAPT Therapeutics, Raises Price Target to $31
Portfolio Pulse from jenniferd'souza@benzinga.com
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on RAPT Therapeutics and raises the price target from $28 to $31.
August 14, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on RAPT Therapeutics and raises the price target from $28 to $31, which could positively impact the stock.
The raised price target by Piper Sandler indicates a positive outlook for RAPT Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100